In hematological malignancies (leukemia, lymphomas, and myelomas) mutations in epigenetic modifiers such as JAK2, DNMT3A, IDH2, or EZH2 are common hallmarks of these diseases [32,33,34]. Here, EZH2 is linked to plasma cell myeloma.